TerraPower Isotopes and launches Ac-225 bisPSMA program
Highlights
• Agreement signed with TerraPower Isotopes (TerraPower) for the supply of the therapeutic alphaemitting isotope, actinium-225 (Ac-225 or 225Ac), for Clarity’s first Targeted Alpha-particle Therapy (TAT) program with bisPSMA.
• Clarity is now well positioned to develop a best-in-class TAT 225Ac-bisPSMA product with secure supply combined with the increased uptake and retention of bisPSMA in tumours.
• TerraPower has a unique Ac-225 manufacturing process that has the potential to provide the scale and dependability needed for commercial manufacturing at a purity level appropriate for clinical use.
• Clarity will continue adding Ac-225 suppliers to its network as the manufacturing process continues to develop and progress to meet standards for clinical and commercial use.
• Clarity will continue to focus on 67Cu-SAR-bisPSMA as its key program in PSMA-expressing prostate cancer because of the proven efficacy and robust safety profile of beta emitters affords an opportunity to target first line therapy, while 225Ac-bisPSMA has potential to provide benefits to patients in later-stage disease.
• Developing both alpha- and beta-emitting therapies puts Clarity in a unique position to offer powerful treatment approaches to improve outcomes for prostate cancer patients.
